Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

355 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Lorlatinib in pretreated ALK- or ROS1-positive lung cancer and impact of TP53 co-mutations: results from the German early access program.
Frost N, Christopoulos P, Kauffmann-Guerrero D, Stratmann J, Riedel R, Schaefer M, Alt J, Gütz S, Christoph DC, Laack E, Faehling M, Fischer R, Fenchel K, Haen S, Heukamp L, Schulz C, Griesinger F. Frost N, et al. Among authors: riedel r. Ther Adv Med Oncol. 2021 Feb 9;13:1758835920980558. doi: 10.1177/1758835920980558. eCollection 2021. Ther Adv Med Oncol. 2021. PMID: 33613692 Free PMC article.
Structural Alterations of MET Trigger Response to MET Kinase Inhibition in Lung Adenocarcinoma Patients.
Plenker D, Bertrand M, de Langen AJ, Riedel R, Lorenz C, Scheel AH, Müller J, Brägelmann J, Daßler-Plenker J, Kobe C, Persigehl T, Kluge A, Wurdinger T, Schellen P, Hartmann G, Zacherle T, Menon R, Thunnissen E, Büttner R, Griesinger F, Wolf J, Heukamp L, Sos ML, Heuckmann JM. Plenker D, et al. Among authors: riedel r. Clin Cancer Res. 2018 Mar 15;24(6):1337-1343. doi: 10.1158/1078-0432.CCR-17-3001. Epub 2017 Dec 28. Clin Cancer Res. 2018. PMID: 29284707
Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer.
Kron A, Alidousty C, Scheffler M, Merkelbach-Bruse S, Seidel D, Riedel R, Ihle MA, Michels S, Nogova L, Fassunke J, Heydt C, Kron F, Ueckeroth F, Serke M, Krüger S, Grohe C, Koschel D, Benedikter J, Kaminsky B, Schaaf B, Braess J, Sebastian M, Kambartel KO, Thomas R, Zander T, Schultheis AM, Büttner R, Wolf J. Kron A, et al. Among authors: riedel r. Ann Oncol. 2018 Oct 1;29(10):2068-2075. doi: 10.1093/annonc/mdy333. Ann Oncol. 2018. PMID: 30165392 Free PMC article.
Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial.
Michels S, Massutí B, Schildhaus HU, Franklin J, Sebastian M, Felip E, Grohé C, Rodriguez-Abreu D, Abdulla DSY, Bischoff H, Brandts C, Carcereny E, Corral J, Dingemans AC, Pereira E, Fassunke J, Fischer RN, Gardizi M, Heukamp L, Insa A, Kron A, Menon R, Persigehl T, Reck M, Riedel R, Rothschild SI, Scheel AH, Scheffler M, Schmalz P, Smit EF, Limburg M, Provencio M, Karachaliou N, Merkelbach-Bruse S, Hellmich M, Nogova L, Büttner R, Rosell R, Wolf J. Michels S, et al. Among authors: riedel r. J Thorac Oncol. 2019 Jul;14(7):1266-1276. doi: 10.1016/j.jtho.2019.03.020. Epub 2019 Apr 9. J Thorac Oncol. 2019. PMID: 30978502 Free article. Clinical Trial.
Overall survival and central nervous system activity of crizotinib in ROS1-rearranged lung cancer-final results of the EUCROSS trial.
Michels S, Massutí B, Vasyliv I, Stratmann J, Frank J, Adams A, Felip E, Grohé C, Rodriguez-Abreu D, Bischoff H, Carcereny I Costa E, Corral J, Pereira E, Fassunke J, Fischer RN, Insa A, Koleczko S, Nogova L, Reck M, Reutter T, Riedel R, Schaufler D, Scheffler M, Weisthoff M, Provencio M, Merkelbach-Bruse S, Hellmich M, Sebastian M, Büttner R, Persigehl T, Rosell R, Wolf J. Michels S, et al. Among authors: riedel r. ESMO Open. 2024 Feb;9(2):102237. doi: 10.1016/j.esmoop.2024.102237. Epub 2024 Feb 12. ESMO Open. 2024. PMID: 38350336 Free PMC article.
Clinicopathologic and molecular characteristics of small-scale ROS1-mutant non-small cell lung cancer (NSCLC) patients.
Glaser M, Rasokat A, Prang D, Nogova L, Wömpner C, Schmitz J, Bitter E, Terjung I, Eisert A, Fischer R, John F, von Levetzow C, Michels S, Riedel R, Ruge L, Scharpenseel H, Siebolts U, Merkelbach-Bruse S, Buettner R, Brägelmann J, Wolf J, Scheffler M. Glaser M, et al. Among authors: riedel r. Lung Cancer. 2023 Oct;184:107344. doi: 10.1016/j.lungcan.2023.107344. Epub 2023 Aug 12. Lung Cancer. 2023. PMID: 37579577 Free article.
Genetic Heterogeneity of MET-Aberrant NSCLC and Its Impact on the Outcome of Immunotherapy.
Kron A, Scheffler M, Heydt C, Ruge L, Schaepers C, Eisert AK, Merkelbach-Bruse S, Riedel R, Nogova L, Fischer RN, Michels S, Abdulla DSY, Koleczko S, Fassunke J, Schultheis AM, Kron F, Ueckeroth F, Wessling G, Sueptitz J, Beckers F, Braess J, Panse J, Grohé C, Hamm M, Kabitz HJ, Kambartel K, Kaminsky B, Krueger S, Schulte C, Lorenz J, Lorenzen J, Meister W, Meyer A, Kappes J, Reinmuth N, Schaaf B, Schulte W, Serke M, Buettner R, Wolf J. Kron A, et al. Among authors: riedel r. J Thorac Oncol. 2021 Apr;16(4):572-582. doi: 10.1016/j.jtho.2020.11.017. Epub 2020 Dec 9. J Thorac Oncol. 2021. PMID: 33309988 Free article.
Rebiopsy in advanced non-small cell lung cancer, clinical relevance and prognostic implications.
Scheffler M, Wiesweg M, Michels S, Nogová L, Kron A, Herold T, Scheel AH, Metzenmacher M, Eberhardt WE, Reis H, Fassunke J, Darwiche K, Aigner C, Schaufler D, Riedel R, Fischer R, Koleczko S, Schildhaus HU, Merkelbach-Bruse S, Schmid KW, Büttner R, Wolf J, Schuler M. Scheffler M, et al. Among authors: riedel r. Lung Cancer. 2022 Jun;168:10-20. doi: 10.1016/j.lungcan.2022.04.006. Epub 2022 Apr 16. Lung Cancer. 2022. PMID: 35461051
MET Fusions in NSCLC: Clinicopathologic Features and Response to MET Inhibition.
Riedel R, Fassunke J, Scheel AH, Scheffler M, Heydt C, Nogova L, Michels S, Fischer RN, Eisert A, Scharpenseel H, John F, Ruge L, Schaufler D, Siemanowski J, Ihle MA, Wagener-Ryczek S, Pappesch R, Rehker J, Bunck A, Kobe C, Keil F, Merkelbach-Bruse S, Büttner R, Wolf J. Riedel R, et al. J Thorac Oncol. 2024 Jan;19(1):160-165. doi: 10.1016/j.jtho.2023.06.020. Epub 2023 Jul 8. J Thorac Oncol. 2024. PMID: 37429463
355 results